Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | SORD | Q00796 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11981508 | 0.89 | MEN1 (0.62) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL11960311 | 0.80 | MEN1 (0.51) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7486793 | 0.79 | HTR1A (0.53) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL22148449 | 0.77 | HRH4 (0.58) | MEN1KMT2AHRH4ALDH1A1KDM4E | |
| SCHEMBL30788620 | 0.77 | HRH4 (0.58) | MEN1KMT2AHRH4ALDH1A1KDM4E | |
| SCHEMBL793547 | 0.77 | HRH4 (0.51) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL30011158 | 0.77 | HRH4 (0.51) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5792508 | 0.77 | CRHBP (0.60) | HRH4SMN1; SMN2MAPT | |
| SCHEMBL13033015 | 0.76 | SORD (0.54) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL13033969 | 0.75 | ACHE (0.56) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2640722-B1 | PYRAZOLOPYRIDINES AND THEIR USE AS TYK2 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-11-04 | — | — | EP | disclosed |
| WO-2015091584-A1 | THIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND THEIR USE AS TYK2 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| EP-2547338-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| CN-102869359-A | Imidazopyridine and purine compounds, compositions, and methods of use | HOFFMANN LA ROCHE | 2013-01-09 | — | — | CN | disclosed |
| WO-2012066061-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDINES AND THEIR USE AS TYK2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012035039-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| WO-2011113802-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011113802-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TYK2, IRAK1, IRAK4 | MEN1 4055/4885KMT2A 2005/4885CYP3A4 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.